Keywords: GlaxoSmithKline, Chiome Bioscience, Monoclonal antibodies, MAbs, Cacner nd autoimmune diseases
GlaxoSmithKline links with Japan's Chiome on MAbs
Article | 10 April 2012
UK pharma giant GlaxoSmithKline group (LSE: GSK) and Tokyo, Japan-based biotech-venture company Chiome Bioscience (TYO:4583) have entered into a pilot ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
